^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
Published date:
05/16/2018
Excerpt:
In the EGFR+ cohort, the primary endpoint was reached as 54 pts in the G+F group were non-progressive at 9 months...Addition of fulvestrant to EGFR-TKI is feasible and is associated with good PFS in the EGFR mutated group.
Secondary therapy:
fulvestrant
DOI:
10.1200/JCO.2018.36.15_suppl.9097
Trial ID:
